From a safety perspective how do you counsel your patients in whom you are beginning PCSK9 inhibitor therapy?

From a safety perspective how do you counsel your patients in whom you are beginning PCSK9 inhibitor therapy?

CLICK HERE FOR CME CREDIT

From a safety perspective how do you counsel your patients in whom you are beginning PCSK9 inhibitor therapy?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Presenter

Matthew Roe, MD

Matthew Roe, MD

Professor of Medicine Duke Clinical Research Institute Duke University School of Medicine Durham, NC